Literature DB >> 16126940

Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production.

J Voswinkel1, A Müller, P Lamprecht.   

Abstract

In Wegener's granulomatosis (WG), antiproteinase 3 (PR3) autoantibodies (PR3-ANCA) are crucial in the development of generalized vasculitis. Wegener's pathognomonic lesion, a granulomatous inflammation of the upper and lower respiratory tract, contains abundant lymphocytes and macrophages. Lymphocyte clusters in germinal center-like formation within the granulomatous lesion are frequently observed, which suggests antigen-driven B cell maturation. Wegener's autoantigen PR3, the target for autoreactive B and T cells, is expressed in granulomatous lesions. Disease progression in WG is accompanied by a profound generalized alteration of T cell differentiation with an increase of effector memory T cells (CD4(+)CD28(-)). The cytokine profile suggests an aberrant Th1-type response either to an environmental trigger and/or the autoantigen PR3 itself. Staphylococcus aureus, a risk factor for disease exacerbation, is widely present in the upper airways in WG. The Ig gene repertoire from WG lesions indicates a predominance of VH3+ B cells with affinity to PR3 as well as to the S. aureus B cell superantigen SPA. Hence, within the WG lesion, S. aureus might support the maturation of PR3-affinity B cells that enter a germinal center reaction in contact with PR3 and T cells and expand, leading to PR3-ANCA production. Thus, granulomatous lesions could represent a potential lymphoid tissue-maintaining autoantibody production rather than a simple, random leukocyte accumulation in WG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126940     DOI: 10.1196/annals.1361.042

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  Pathogenesis of ANCA-Associated Pulmonary Vasculitis.

Authors:  Marco A Alba; J Charles Jennette; Ronald J Falk
Journal:  Semin Respir Crit Care Med       Date:  2018-11-07       Impact factor: 3.119

Review 2.  Updates in ANCA-associated vasculitis.

Authors:  Christian Pagnoux
Journal:  Eur J Rheumatol       Date:  2016-01-29

Review 3.  Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.

Authors:  Eva Schrezenmeier; David Jayne; Thomas Dörner
Journal:  J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 10.121

4.  High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations.

Authors:  Annette Bruchfeld; Mårten Wendt; Johan Bratt; Abdul R Qureshi; Sangeeta Chavan; Kevin J Tracey; Karin Palmblad; Iva Gunnarsson
Journal:  Mol Med       Date:  2010-09-10       Impact factor: 6.354

Review 5.  T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?

Authors:  Benjamin Wilde; Marielle Thewissen; Jan Damoiseaux; Pieter van Paassen; Oliver Witzke; Jan Willem Cohen Tervaert
Journal:  Arthritis Res Ther       Date:  2010-02-24       Impact factor: 5.156

Review 6.  ANCA-associated vasculitis: from bench research to novel treatments.

Authors:  Lalit Pallan; Caroline O Savage; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

Review 7.  Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

Review 8.  Ectopic lymphoid tissues and local immunity.

Authors:  Damian M Carragher; Javier Rangel-Moreno; Troy D Randall
Journal:  Semin Immunol       Date:  2008-02-19       Impact factor: 11.130

Review 9.  Classification of ANCA-associated vasculitis: differences based on ANCA specificity and clinicopathologic phenotype.

Authors:  Maricruz Domínguez-Quintana; Marco A Alba; Andrea Hinojosa-Azaola
Journal:  Rheumatol Int       Date:  2021-08-12       Impact factor: 2.631

10.  Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis?

Authors:  Ruth Tarzi; Charles Pusey
Journal:  Nat Rev Nephrol       Date:  2013-10-01       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.